Bausch Health Companies Inc.
BHC
Health Care
2
exclusion reasons
1 theme
Bausch Health Companies Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Bausch Health Companies Inc. develops and markets a portfolio of pharmaceutical products and medical devices, a business model that inherently relies on animal testing for research, development, and regulatory compliance. The company acknowledges this reliance in its public ethics statements, which require testing facilities to maintain standards "as mandated by law."
This reliance has resulted in significant legal penalties for animal welfare violations. In 2016, a Bausch Health animal research facility agreed to pay an unprecedented $3.5 million penalty to settle allegations of animal cruelty, a case highlighted by animal welfare groups as a landmark cost for such violations. More recently, in 2026, a $17.85 million settlement was reached with state authorities concerning Medicaid fraud and patient abuse, which included associated animal cruelty charges. These repeated, high-penalty enforcement actions indicate systemic failures in animal care within the company's operations.
Bausch Health Companies Inc. develops, manufactures, and markets a portfolio of pharmaceutical, medical device, and over-the-counter health products. As a global pharmaceutical company, its core business of bringing new drugs and medical devices to market inherently requires animal testing to satisfy regulatory requirements for safety and efficacy. The company acknowledges this requirement in its Clinical Trials Policy, stating, "When animal testing is required... we are committed to utilizing the absolute minimum."
The company's product portfolio and pipeline are dependent on animal studies. For example, its prescription products like ARESTIN® for periodontal disease and Migranal nasal spray for migraines required animal data for FDA approval. Its subsidiary, Bausch + Lomb, also develops ophthalmic pharmaceuticals and devices that undergo animal testing. While the FDA and industry are exploring animal-free testing methods for some applications, such as certain monoclonal antibodies, regulatory approval for most new chemical entities and medical devices from Bausch Health continues to necessitate animal data. The company's business model is fundamentally tied to the animal testing required by global health authorities.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.